CTN / CTA
CTN vs CTA in Australia for overseas sponsors
For overseas companies planning an Australian clinical trial, CTN and CTA are often the first regulatory terms that appear in planning discussions.
The key point is that the Australian sponsor is the entity that submits the relevant CTN or CTA activity to the TGA.
Short answer
CTN is a notification pathway and CTA is an approval pathway involving TGA review of limited scientific data before the trial starts. Which pathway is appropriate depends on the product, risk profile, protocol, available evidence, and HREC expectations.
Plain English
CTN is not the same as CTA.
Under the CTN scheme, the TGA does not evaluate clinical trial data at the time of notification. The protocol, scientific rationale, risk-benefit position, and ethical acceptability are considered through the HREC and site governance process.
Under the CTA scheme, the TGA reviews relevant scientific data before the clinical trial starts. CTA may be considered where additional TGA review is appropriate because of product novelty, risk, limited prior human experience, or the nature of the therapeutic good.
Sponsor role
The Australian sponsor is the TGA-facing sponsor.
For overseas sponsors, the practical issue is not only choosing CTN or CTA. The Australian clinical trial still needs an Australian sponsor entity to hold the local sponsor role.
Clintrail can act as that Australian sponsor and work with the overseas company to define who provides product information, safety inputs, protocol context, site information, insurance and indemnity assumptions, and operational updates.
Decision points
The pathway should be considered early.
The CTN or CTA discussion should happen before Australian startup work accelerates. It affects timing, documentation, HREC expectations, TGA interactions, and the information the local sponsor will need from the overseas company.
- Product type and whether the trial involves unapproved therapeutic goods.
- Prior clinical and non-clinical evidence.
- Novelty of the product, technology, material, analyte, or mechanism.
- HREC access to scientific and technical expertise.
- Whether a medical device, biologic, drug, diagnostics product, or IVD raises pathway-specific questions.
Practical matrix
CTN and CTA compared
This is a planning distinction, not a substitute for pathway advice. The correct pathway needs to be assessed against the specific clinical trial.
| Issue | CTN | CTA |
|---|---|---|
| TGA involvement before startup | Notification to the TGA; data is not evaluated by TGA at notification. | TGA evaluates relevant scientific data before approval. |
| HREC role | HREC assesses the protocol, scientific validity, safety, risk-benefit and ethics. | HREC approval is still required; TGA review does not replace ethics review. |
| Australian sponsor role | The Australian sponsor submits and maintains the notification. | The Australian sponsor submits the CTA application and related activity. |
Common questions
Questions overseas teams usually ask
Can an overseas company submit the CTN directly?
The Australian clinical trial sponsor submits the CTN. An overseas company planning an Australian trial needs an Australian sponsor entity for that role.
Does CTN mean the trial can ignore HREC and site approvals?
No. HREC approval and relevant site or approving authority requirements still need to be in place before the unapproved therapeutic good is supplied for the trial.
Can Clintrail help if we are not sure whether CTN or CTA applies?
Clintrail can discuss the sponsor-structure implications and the information needed to align the Australian sponsor role with the intended pathway. Formal pathway, legal, or regulatory advice may require specialist advisers.
Source context
Grounded in Australian clinical trial requirements.
These pages are written for planning clarity. They do not replace legal, tax, regulatory, insurance, ethics, or clinical operations advice for a specific trial.
Related pages
Continue the sponsor-structure research
Australian clinical trial sponsor responsibilities
What overseas sponsors need to understand about the Australian clinical trial sponsor role, sponsor oversight, approvals, safety, records, and responsibility allocation.
Medical device trials in Australia with a local sponsor
How overseas medical device companies can use an Australian local sponsor for Australian clinical trials, including device-specific sponsor considerations.
IVD and diagnostics trials in Australia with a local sponsor
How overseas diagnostics and IVD companies can structure Australian clinical performance or diagnostics studies with an Australian local sponsor.
Run a clinical trial in Australia without setting up a local entity
How overseas companies can avoid forming an Australian subsidiary solely to hold the clinical trial sponsor role.
Next step
Need an Australian local sponsor?
Send through a short description of the clinical trial and your planned Australian activity. We will review it and get back to you soon.